{"id":"c-beam-regimen","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Cardiotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"C-BEAM is a myeloablative conditioning regimen designed to eliminate malignant cells and suppress the patient's immune system to allow engraftment of donor stem cells. The combination of four chemotherapy agents targets rapidly dividing cells and provides broad cytotoxic coverage. This regimen is used primarily in lymphoid malignancies to prepare patients for allogeneic or autologous stem cell transplantation.","oneSentence":"C-BEAM is a chemotherapy regimen combining carmustine, etoposide, cytarabine, and melphalan used as conditioning therapy before hematopoietic stem cell transplantation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:36.085Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Conditioning regimen for hematopoietic stem cell transplantation in lymphomas and other hematologic malignancies"}]},"trialDetails":[{"nctId":"NCT04047628","phase":"PHASE3","title":"Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-19","conditions":"Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis","enrollment":156},{"nctId":"NCT07268339","phase":"PHASE3","title":"A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer.","status":"NOT_YET_RECRUITING","sponsor":"The Christie NHS Foundation Trust","startDate":"2025-12-01","conditions":"High-Risk Non-Muscle Invasive Bladder Cancer","enrollment":328},{"nctId":"NCT06377540","phase":"PHASE2","title":"MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-12-04","conditions":"Autologous Stem Cell Transplant, Classic Hodgkin Lymphoma","enrollment":28},{"nctId":"NCT02797470","phase":"PHASE1, PHASE2","title":"Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"AIDS Malignancy Consortium","startDate":"2016-06-23","conditions":"HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Plasmablastic Lymphoma","enrollment":11},{"nctId":"NCT01476839","phase":"PHASE1","title":"Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2012-11-09","conditions":"Recurrent Adult Hodgkin Lymphoma","enrollment":25},{"nctId":"NCT02342782","phase":"PHASE1","title":"Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2020-06-08","conditions":"Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT05651451","phase":"NA","title":"Effect of Laser Acupuncture on Metabolic Syndrome in Obese Postmenopausal Women","status":"COMPLETED","sponsor":"Cairo University","startDate":"2022-12-22","conditions":"Metabolic Syndrome","enrollment":30},{"nctId":"NCT05029206","phase":"","title":"Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis in Sweden","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2021-05-05","conditions":"Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting","enrollment":174},{"nctId":"NCT01035463","phase":"PHASE1, PHASE2","title":"Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2009-11-12","conditions":"Anaplastic Large Cell Lymphoma, ALK-Negative, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma","enrollment":74},{"nctId":"NCT00571493","phase":"PHASE1, PHASE2","title":"VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2006-04-14","conditions":"Non-hodgkin's Lymphoma, Mantle Cell Lymphoma","enrollment":42},{"nctId":"NCT01484093","phase":"PHASE1, PHASE2","title":"Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-11-29","conditions":"Mantle Cell Lymphoma","enrollment":96},{"nctId":"NCT05931263","phase":"PHASE3","title":"A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-06-01","conditions":"Newly Diagnosed Peripheral T-cell Lymphoma","enrollment":104},{"nctId":"NCT05814718","phase":"NA","title":"Modified BEAM Regimen for T Cell Lymphoma Underwent ASCT","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2023-04-15","conditions":"Autologous Stem Cell Transplantation, Conditioning","enrollment":122},{"nctId":"NCT05228249","phase":"PHASE1","title":"Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma","status":"WITHDRAWN","sponsor":"Fred Hutchinson Cancer Center","startDate":"2023-04","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","enrollment":""},{"nctId":"NCT03570983","phase":"PHASE2","title":"A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion","status":"UNKNOWN","sponsor":"Swedish Medical Center","startDate":"2018-09-05","conditions":"Multiple Myeloma","enrollment":100},{"nctId":"NCT04143984","phase":"PHASE2","title":"Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Shanghai Proton and Heavy Ion Center","startDate":"2021-01-19","conditions":"Nasopharyngeal Carcinoma","enrollment":146},{"nctId":"NCT02059239","phase":"PHASE1, PHASE2","title":"Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2014-06-04","conditions":"Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma","enrollment":34},{"nctId":"NCT02504359","phase":"PHASE1","title":"Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2015-07-20","conditions":"Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma","enrollment":11},{"nctId":"NCT00536978","phase":"PHASE2","title":"Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-09","conditions":"Lymphoma, Leukemia","enrollment":22},{"nctId":"NCT00345865","phase":"PHASE2","title":"Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2005-08-24","conditions":"Lymphoma","enrollment":473},{"nctId":"NCT04442750","phase":"NA","title":"Different Concentrations of Bupivacaine in Erector Spinae Plane Block in Hip Surgeries","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2020-06-22","conditions":"Postoperative Pain","enrollment":100},{"nctId":"NCT00992446","phase":"PHASE2","title":"Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2010-09-02","conditions":"Adult Diffuse Large B-Cell Lymphoma, B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma","enrollment":27},{"nctId":"NCT00068692","phase":"PHASE3","title":"Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-10-15","conditions":"Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma, Recurrent Rectal Carcinoma","enrollment":225},{"nctId":"NCT01969435","phase":"PHASE2","title":"Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2014-03-19","conditions":"Hodgkin Disease, Lymphoma, Non-Hodgkin","enrollment":50},{"nctId":"NCT02354313","phase":"PHASE3","title":"Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult Patients","status":"UNKNOWN","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2010-05","conditions":"MANTLE CELL LYMPHOMA","enrollment":300},{"nctId":"NCT00281879","phase":"PHASE2","title":"Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2006-02","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":200},{"nctId":"NCT00288626","phase":"PHASE2","title":"High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-07","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":25},{"nctId":"NCT01653418","phase":"PHASE2","title":"Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2012-09","conditions":"Multiple Myeloma","enrollment":10},{"nctId":"NCT00209222","phase":"PHASE3","title":"Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL","status":"UNKNOWN","sponsor":"European Mantle Cell Lymphoma Network","startDate":"2004-07","conditions":"Lymphoma, Mantle-Cell","enrollment":360},{"nctId":"NCT00505921","phase":"PHASE2","title":"Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2003-03","conditions":"Lymphoma","enrollment":27},{"nctId":"NCT00946374","phase":"PHASE2","title":"Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma","status":"UNKNOWN","sponsor":"Heidelberg University","startDate":"2004-07","conditions":"Mantle-Cell Lymphoma","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"C-BEAM Regimen","genericName":"C-BEAM Regimen","companyName":"The First Affiliated Hospital with Nanjing Medical University","companyId":"the-first-affiliated-hospital-with-nanjing-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"C-BEAM is a chemotherapy regimen combining carmustine, etoposide, cytarabine, and melphalan used as conditioning therapy before hematopoietic stem cell transplantation. Used for Conditioning regimen for hematopoietic stem cell transplantation in lymphomas and other hematologic malignancies.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}